Adaptive Biotechnologies CORP Form 4 insider transactions

Adaptive Biotechnologies CEO and Chairman Chad M. Robins sold 124,998 shares of common stock for a weighted average price of $15.59 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised options and sold 3,125 shares of common stock for a profit, pursuant to a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and subsequently sold 4,394 shares of common stock on December 22, 2025, under a Rule 10b5-1 trading plan.

Adaptive Biotechnologies' Chief People Officer, Francis Lo, executed a pre-planned sale of 113,890 shares after exercising stock options.

Adaptive Biotechnologies Director Robert Hershberg sold 22,968 shares of common stock at $16 per share.

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, executed a pre-planned sale of 12,604 common shares following option exercises.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold a total of 37,212 shares of common stock in early December 2025 under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and subsequently sold a significant number of common shares under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies CEO Chad M. Robins sold 160,734 shares of common stock in late 2025 through a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, exercised stock options and subsequently sold a significant number of shares under a pre-arranged 10b5-1 trading plan.

Adaptive Biotechnologies' CFO, Kyle Piskel, sold 238 shares of common stock in a non-discretionary transaction to cover tax withholding related to RSU vesting.

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 10,000 shares of common stock for a weighted average price of $14.82 per share.

Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported the sale of 89,265 shares of common stock over three days in November 2025, pursuant to a Rule 10b5-1 trading plan.

Kyle Piskel, CFO of Adaptive Biotechnologies, sold 1,929 shares of common stock on May 16, 2025, to cover tax withholding obligations related to the vesting of RSUs.

Chief Financial Officer Kyle Piskel of Adaptive Biotechnologies Corp. reports acquisition and disposition of company stock to cover tax obligations.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, exercised stock options on March 14, 2025, acquiring 2,500 shares of common stock.

Director Michelle Griffin sold 36,291 shares of Adaptive Biotechnologies Corp (ADPT) at an average price of $7.19 on March 13, 2025.

Robert Hershberg, a director at Adaptive Biotechnologies Corp, sold 53,000 shares of common stock on March 12, 2025, at a price of $7.59 per share.

Director Peter Neupert of Adaptive Biotechnologies Corp. exercised stock options and sold shares on March 10, 2025.

Francis Lo, Chief People Officer of Adaptive Biotechnologies, reports the acquisition and disposal of company stock and stock options related to vesting RSUs and tax obligations.

Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, reports acquisition and disposal of company stock and stock options related to vesting of RSUs.

Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, reports acquisition and disposition of company stock to cover tax obligations related to vesting RSUs.

Julie Rubinstein, President and COO of Adaptive Biotechnologies, reports acquisition and disposal of company stock to cover tax obligations related to RSU vesting.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reports acquisition and disposal of common stock to cover tax obligations related to RSU vesting.

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, reports the acquisition and disposal of common stock related to RSU vesting and tax obligations.

Michael J Pellini, a director of Adaptive Biotechnologies, reported acquiring shares and stock options on March 4, 2025.

Director Katey Einterz Owen reports acquisition of common stock and stock options in Adaptive Biotechnologies Corp.